Co-Diagnostics, Inc. 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File No. 001-38148 CO-DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Utah 46-2609396 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 2401 S. Foothill Drive , Suite D , Salt Lake City , Utah 84109 (Address of principal executive offices and zip code) (801) 438-1036 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock CODX The Nasdaq Capital Market Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☒ Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒ As of November 9, 2021, there were 28,894,890 shares of common stock, par value $0.001 per share, outstanding. CO-DIAGNOSTICS, INC . TABLE OF CONTENTS PART I FINANCIAL INFORMATION: Item 1. Financial Statements (unaudited): 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations 4 Condensed Consolidated Statements of Cash Flows 5 Condensed Consolidated Statements of Stockholders’ Equity 6 Notes to Condensed Consolidated Financial Statements 7 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3. Quantitative and Qualitative Disclosures About Market Risk 21 Item 4. Controls and Procedures 21 PART II OTHER INFORMATION: Item 1. Legal Proceedings 21 Item 1A. Risk Factors 22 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 22 Item 3. Defaults Upon Senior Securities 22 Item 4. Mine Safety Disclosures 22 Item 5. Other Information 22 Item 6. Exhibits 23 Signatures 24 2 PART I. FINANCIAL INFORMATION Item 1. Financial Statements CO – DIAGNOSTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) September 30, 2021 December 31, 2020 Assets Current assets Cash and cash equivalents $ 82,658,248 $ 42,976,713 Marketable investment securities 1,251,285 4,335,446 Accounts receivable, net 14,589,599 12,136,833 Inventory 3,302,925 7,995,189 Prepaid expenses 485,095 369,028 Total current assets 102,287,152 67,813,209 Property and equipment, net 1,524,806 949,639 Investment in joint venture 1,034,098 1,927,125 Deferred tax asset 512,552 547,224 Total assets $ 105,358,608 $ 71,237,197 Liabilities and stockholders’ equity Current liabilities Accounts payable $ 800,003 $ 598,318 Accrued expenses, current 2,055,698 2,849,503 Accrued expenses (related party), current 30,000 120,000 Income taxes payable 1,044,640 637,560 Deferred revenue 189,556 305,307 Total current liabilities 4,119,897 4,510,688 Long-term liabilities Accrued expenses, noncurrent 1,080,358 - Accrued expenses (related party), noncurrent - 30,000 Total long-term liabilities 1,080,358 30,000 Total liabilities 5,200,255 4,540,688 Commitments and contingencies (Note 9) - - Stockholders’ equity Convertible preferred stock, $ 0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of September 30, 2021 and December 31, 2020 - - Common stock, $ 0.001 par value; 100,000,000 shares authorized; 28,894,890 and 28,558,033 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively 28,895 28,558 Additional paid-in capital 53,458,589 49,157,236 Accumulated earnings 46,670,869 17,510,715 Total stockholders’ equity 100,158,353 66,696,509 Total liabilities and stockholders’ equity $ 105,358,608 $ 71,237,197 See accompanying notes to unaudited condensed consolidated financial statements 3 CO – DIAGNOSTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Revenue $ 30,101,353 $ 21,818,753 $ 77,484,262 $ 47,407,555 Cost of revenue 3,311,255 5,821,281 9,088,175 12,278,326 Gross profit 26,790,098 15,997,472 68,396,087 35,129,229 Operating expenses Sales and marketing 4,253,091 798,474 11,303,950 1,457,148 General and administrative 2,919,498 2,203,417 8,323,620 5,853,935 Research and development 5,893,350 921,889 12,779,573 2,072,160 Depreciation and amortization 94,038 35,490 232,757 81,456 Total operating expenses 13,159,977 3,959,270 32,639,900 9,464,699 Income from operations 13,630,121 12,038,202 35,756,187 25,664,530 Other income (expense) Interest income 11,379 29,992 36,565 75,740 Gain (loss) on equity method investment in joint venture ( 64,940 ) 748,557 ( 401,288 ) 1,016,297 Total other income (expense) ( 53,561 ) 778,549 ( 364,723 ) 1,092,037 Income before income taxes 13,576,560 12,816,751 35,391,464 26,756,567 Income tax provision (benefit) 2,100,594 ( 2,914,781 ) 6,231,310 ( 2,914,781 ) Net income $ 11,475,966 $ 15,731,532 $ 29,160,154 $ 29,671,348 Earnings per common share: Basic $ 0.40 $ 0.56 $ 1.01 $ 1.13 Diluted $ 0.38 $ 0.53 $ 0.98 $ 1.07 Weighted average shares outstanding: Basic 28,941,357 28,084,267 28,800,450 26,172,439 Diluted 29,952,690 29,597,792 29,872,415 27,621,531 See accompanying notes to unaudited condensed consolidated financial statements 4 CO – DIAGNOSTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Nine Months Ended September 30, 2021 2020 Cash flows from operating activities Net income $ 29,160,154 $ 29,671,348 Adjustments to reconcile net income to cash used in operating activities: Depreciation and amortization 232,757 81,456 Stock-based compensation expense 3,851,293 2,167,376 Loss (gain) from equity method investment 401,288 ( 1,016,297 ) Deferred income taxes 34,672 ( 2,914,781 ) Bad debt expense 156,011 - Changes in assets and liabilities: Accounts receivable ( 2,608,777 ) ( 10,509,035 ) Prepaid expenses ( 116,068 ) ( 22,076 ) Inventory 4,432,048 ( 10,647,034 ) Deferred revenue ( 115,751 ) 739,781 Income taxes payable 692,823 - Accounts payable and accrued expenses 82,495 656,602 Net cash provided by operating activities 36,202,945 8,207,340 Cash flows from investing activities Purchases of property and equipment ( 547,708 ) ( 305,683 ) Purchases of marketable investment securities - ( 9,310,000 ) Proceeds from maturities of marketable investment securities 3,084,161 3,260,000 Investment in joint venture 491,739 ( 714,500 ) Net cash provided by (used in) investing activities 3,028,192 ( 7,070,183 ) Cash flows from financing activities Proceeds from sale of common stock - 19,470,005 Proceeds from exercise of options and warrants 450,398 1,187,984 Payment of offering costs - ( 1,457,922 ) Net cash provided by financing activities 450,398 19,200,067 Net increase in cash and cash equivalents 39,681,535 20,337,224 Cash and cash equivalents at beginning of period 42,976,713 893,138 Cash and cash equivalents at end of period $ 82,658,248 $ 21,230,362 Supplemental disclosure of cash flow information Interest paid $ - $ - Income taxes paid $ 4,733,200 $ - Supplemental disclosure of non-cash investing and financing transactions Inventory moved to property, plant and equipment $ 260,216 $ 117,220 See accompanying notes to unaudited condensed consolidated financial statements 5 CO – DIAGNOSTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Unaudited) Convertible Preferred Stock Common Stock Additional Paid-in Accumulated Earnings Total Stockholders’ Shares Amount Shares Amount Capital (Deficit) Equity Balance as of December 31, 2020 - $ - 28,558,033 $ 28,558 $ 49,157,236 $ 17,510,715 $ 66,696,509 Public offering, net of offering costs of $ 1,457,922 Public offering, net of offering costs of $ 1,457,922 , shares Common stock issued for warrant exercises Common stock issued for warrant exercises, shares Common stock issued for option exercises - - 65,891 66 148,914 - 148,980 Common stock issued for option and warrant exercises Common stock issued for option and warrant exercises, shares Stock-based compensation - - 41,790 42 1,512,970 - 1,513,012 Conversion of preferred stock to common Conversion of preferred stock to common, shares Net income - - - - - 7,898,975 7,898,975 Balance as of March 31, 2021 - $ - 28,665,714 $ 28,666 $ 50,819,120 $ 25,409,690 $ 76,257,476 Common stock issued for option exercises - - 118,334 118 295,799 - 295,917 Stock-based compensation - - 105,842 106 927,231 - 927,337 Net income - - - - - 9,785,213 9,785,213 Balance as of June 30, 2021 - $ - 28,889,890 $ 28,890 $ 52,042,150 $ 35,194,903 $ 87,265,943 Common stock issued for option exercises - - 5,000 5 5,495 - 5,500 Stock-based compensation - - - - 1,410,944 - 1,410,944 Net income - - - - - 11,475,966 11,475,966 Balance as of September 30, 2021 - $ - 28,894,890 $ 28,895 $ 53,458,589 $ 46,670,869 $ 100,158,353 Balance as of December 31, 2019 25,600 $ 26 17,342,922 $ 17,343 $ 26,687,701 $ ( 24,967,814 ) $ 1,737,256 Public offering, net of offering costs of $ 1,457,922 - - 7,242,954 7,243 18,004,840 - 18,012,083 Common stock issued for warrant exercises - - 719,492 720 49,280 - 50,000 Stock-based compensation expense - - 12,363 12 432,811 - 432,823 Conversion of preferred stock to common ( 25,600 ) ( 26 ) 2,133,333 2,133 ( 2,107 ) - - Net loss - - - - - ( 1,065,193 ) ( 1,065,193 ) Balance as of March 31, 2020 - $ - 27,451,064 $ 27,451 $ 45,172,525 $ ( 26,033,007 ) $ 19,166,969 Common stock issued for option and warrant exercises - - 530,289 530 862,935 - 863,465 Stock-based compensation expense - - 9,689 10 691,409 - 691,419 Net income - - - - - 15,005,009 15,005,009 Balance as of June 30, 2020 - $ - 27,991,042 $ 27,991 $ 46,726,869 $ ( 11,027,998 ) $ 35,726,862 Common stock issued for option exercises - - 108,334 108 274,410 - 274,518 Stock-based compensation - - 61,883 62 1,043,073 - 1,043,135 Stock-based compensation expense - - 61,883 62 1,043,073 - 1,043,135 Net income - - - - - 15,731,532 15,731,532 Net income (loss) - - - - - 15,731,532 15,731,532 Balance as of September 30, 2020 - $ - 28,161,259 $ 28,161 $ 48,044,352 $ 4,703,534 $ 52,776,047 See accompanying notes to unaudited condensed consolidated financial statements 6 CO – DIAGNOSTICS, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) Note 1 – Overview and Basis of Presentation Description of Business Co-Diagnostics, Inc., a Utah corporation (the “Company” or “Co-Dx”), is developing robust and innovative molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The Company develops, manufactures, and sells reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA). In connection with the sale of these tests, the Company may sell diagnostic equipment and supplies from other manufacturers. Unaudited Condensed Consolidated Financial Statements The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q as they are prescribed for smaller reporting companies and emerging growth companies. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to make the financial statements not misleading have been included. Operating results for the three months ended September 30, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. These statements should be read in conjunction with the Company’s audited financial statements and related notes for the year ended December 31, 2020, included in the Company’s Annual Report on Form 10-K filed on March 25, 2021. Certain 2020 financial statement amounts have been reclassified to conform to 2021 presentations. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Such estimates include receivables and other long-lived assets, legal and regulatory contingencies, income taxes, share based arrangements, and others. These estimates and assumptions are based on management’s best estimates and judgments. Actual amounts and results could differ from those estimates. Note 2 – Summary of Significant Accounting Policies Cash and Cash Equivalents Cash and cash equivalents consist of cash on hand, money market funds and highly liquid investments with an original maturity date of 90 days or less from the date of purchase. The fair value of cash equivalents approximated their carrying value as of September 30, 2021 and December 31, 2020. The Company has its cash and cash equivalents with large creditworthy financial institutions and the balance exceeded federally insured limits. The Company has not experienced any losses in such accounts, and management believes the Company is not exposed to any significant credit risk on cash and cash equivalents. Marketable Investment Securities The Company’s marketable investment securities are comprised of investments in certificates of deposit. The Company determines the appropriate classification of its marketable investment securities at the time of purchase and re-evaluates such designation at each balance sheet date. The Company has classified and accounted for its marketable investment securities as available-for-sale securities as the Company may sell these securities at any time for use in its current operations or for other purposes, even prior to maturity. As a result, the Company classifies its marketable investment securities, including securities with stated maturities beyond twelve months, within current assets in the condensed consolidated balance sheets. Any unrealized gains or losses are immaterial. 7 Accounts Receivable Trade accounts receivable are recorded at the invoiced amount (net of allowance) and do not bear interest. The Company maintains an allowance for doubtful accounts for amounts the Company does not expect to collect. In establishing the required allowance, management considers historical losses, current market condition, customers’ financial condition, the age of receivables, and current payment patterns. Account balances are written off against the allowance once the receivable is deemed uncollectible. Recoveries of trade receivables previously written off are recorded when collected. At September 30, 2021, total accounts receivable was $ 15,347,499 with an allowance for uncollectable accounts of $ 757,900 resulting in a net amount of $ 14,589,599 . At December 31, 2020, total accounts receivable was $ 12,928,633 with an allowance for uncollectable accounts of $ 791,800 resulting in a net amount of $ 12,136,833 . Equity-Method Investments Our equity method investments are initially recorded at cost and are included in other long-term assets in the accompanying condensed consolidated balance sheet. We adjust the carrying value of our investment based on our share of the earnings or losses in the periods which they are reported by the investee until the carrying amount is zero. The earnings or losses are included in other income (expense) in the accompanying condensed consolidated statements of operations. Inventory Inventory is stated at the lower of cost or net-realizable value. Inventory cost is determined on a first-in first-out basis that approximates average cost in accordance with ASC 330-10-30-12. At September 30, 2021, the Company had $ 3,302,925 in inventory, of which $ 925,620 was finished goods and $ 2,377,305 was raw materials. At December 31, 2020, the Company had $ 7,995,189 in inventory, of which $ 598,881 was finished goods and $ 7,396,308 was raw materials. The Company establishes reserves to reduce slow-moving, obsolete, or unusable inventories to their estimated useful or scrap values. Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is provided using the straight-line method over the estimated useful lives of the property, generally from three to five years . Repairs and maintenance costs are expensed as incurred except when such repairs significantly add to the useful life or productive capacity of the asset, in which case the repairs are capitalized. The Company reviews its long-lived assets, including property and equipment, for impairment whenever an event or change in facts and circumstances indicates that their carrying amounts may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount to the estimated undiscounted future cash flows expected to be generated. If the carrying amount exceeds the undiscounted cash flows, the assets are determined to be impaired and an impairment charge is recognized as the amount by which the carrying amount exceeds fair value. Revenue Recognition The Company generates revenue from product sales and license sales. The Company recognizes revenue when all of the following criteria are satisfied: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as the Company satisfies each performance obligation. 8 The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. The Company records any payments received from customers prior to the Company fulfilling its performance obligation(s) as deferred revenue. Deferred Revenue Deferred revenue primarily consists of payments received from customers prior to the Company fulfilling its performance obligation of providing the product. When this occurs, the Company records a contract liability as deferred revenue. Deferred revenue is recognized as revenue as the related performance obligations are satisfied. Research and Development Research and development costs are expensed when incurred. For the three and nine months ended September 30, 2021, the Company expensed $ 5,893,350 and $ 12,779,573 of research and development costs, respectively. For the three and nine months ended September 30, 2020, the Company expensed $ 921,889 and $ 2,072,160 , respectively. Stock-based Compensation The Company has granted stock-based awards, including restricted stock, stock options, stock warrants and restricted stock units (“RSUs”), to its employees, certain consultants and members of its board of directors. The Company records stock-based compensation based on the grant date fair value of the awards and recognizes the fair value of those awards as expense using the straight-line method over the requisite service period of the award. The Company estimates the grant date fair value of stock options using the Black-Scholes option-pricing model. When an award is forfeited prior to the vesting date, the Company recognizes an adjustment for the previously recognized expense in the period of the forfeiture. Income Taxes The Company accounts for income taxes in accordance with the liability method of accounting for income taxes. Under this method, deferred income tax assets and deferred income tax liabilities represent the tax effect of temporary differences between financial reporting and tax reporting measured at enacted tax rates in effect for the year in which the differences are expected to reverse. The Company recognizes only the impact of tax positions that, based on their technical merits, are more likely than not to be sustained upon an audit by the taxing authority. Valuation allowances are provided when it is more-likely-than-not that some or all of the deferred income tax assets may not be realized. In assessing the need for a valuation allowance, the Company has considered its historical levels of income, expectations of future taxable income and ongoing tax planning strategies. Developing the provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred income tax assets and liabilities and any estimated valuation allowances deemed necessary to value deferred income tax assets. Judgments and tax strategies are subject to audit by various taxing authorities. While the Company believes it has no significant uncertain income tax positions in the consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial positions, result of operations, or cash flows. Concentrations Risk and Significant Customers The Company had certain customers which are each responsible for generating 10% or more of the total revenue for the three and nine months ended September 30, 2021. Two customers together accounted for approximately 55 % and 49 %, respectively, of total revenue for the three and nine months ended September 30, 2021. Two customers each accounted for more than 10% of accounts receivable at September 30, 2021 and December 31, 2020. These two customers together accounted for approximately 52 % and 48 % of accounts receivable at September 30, 2021 and December 31, 2020, respectively. 9 Net Income per Share Basic net income or loss per common share is computed by dividing net income or loss applicable to common shareholders by the weighted average number of shares outstanding during each period. Diluted net income or loss per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period increased by common shares that could be issued upon conversion or exercise of other outstanding securities to the extent those additional common shares would be dilutive. The dilutive effect of potentially dilutive securities is reflected in diluted net income or loss per share by application of the treasury stock method. During periods when the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the effects of potentially dilutive securities are anti-dilutive. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption. As an emerging growth company (“EGC”), the Company has elected to take advantage of the benefits of the extended transition period provided for in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards which allows the Company to defer adoption of certain accounting standards until those standards would otherwise apply to private companies. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which requires recognition of leased assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. This update is effective for annual periods and interim periods with those periods beginning after December 15, 2021, for public EGC companies like us. The Company expects to use the modified retrospective transition method with the option to recognize a cumulative-effect adjustment at the date of adoption. The Company expects its balance sheet will be impacted as it records right-of-use assets and lease liabilities on its consolidated balance sheet but does not expect the adoption of this standard will have a material impact on its consolidated statements of operations and cash flows. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326) (“ASU 2016-13”), which requires the measurement and recognition of expected credit losses for certain financial instruments, which includes the Company’s accounts receivable. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. The update is effective for annual periods and interim periods with those periods beginning after December 15, 2021, for public EGC companies like us. The standard requires a cumulative effect adjustment to the balance sheet as of the beginning of the first early reporting period in which the guidance is effective. The Company is evaluating the impact of the adoption of ASU 2016-13 on its consolidated financial statements. Note 3 – Fair Value Measurements The Company measures and records certain financial assets at fair value on a recurring basis. Fair value is based on the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company’s financial instruments that are measured at fair value on a recurring basis consist of money market funds. The following three levels of inputs are used to measure the fair value of financial instruments: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data. 10 The Company’s financial instruments that are measured at fair value on a recurring basis consist of certificates of deposit. The following table summarizes the assets measured at fair value on a recurring basis as of September 30, 2021, and December 31, 2020, by level within the fair value hierarchy: Summary of Assets Measured at Fair Value on Recurring Basis September 30, 2021 (Level 1) (Level 2) (Level 3) Total Marketable investment securities: Certificates of deposit $ - $ 1,251,285 $ - $ 1,251,285 December 31, 2020 (Level 1) (Level 2) (Level 3) Total Marketable investment securities: Certificates of deposit $ - $ 4,335,446 $ - $ 4,335,446 Note 4 – Revenue The following table sets forth revenue by geographic area: Summary of Revenue by Geographic Area Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 United States $ 16,907,574 $ 14,054,316 $ 34,701,035 $ 28,151,446 Rest of World 13,193,779 7,764,437 42,783,227 19,256,109 Total $ 30,101,353 $ 21,818,753 $ 77,484,262 $ 47,407,555 Percentage of revenue by area: United States 56 % 64 % 45 % 59 % Rest of World 44 % 36 % 55 % 41 % Deferred Revenue Changes in the Company’s deferred revenue balance for the nine months ended September 30, 2021 were as follows: Schedule of Deferred Revenue Balance as of December 31, 2020 $ 305,307 Revenue recognized included in deferred revenue balance at the beginning of the period ( 194,964 ) Increase due to prepayments from customers 79,213 Balance as of September 30, 2021 $ 189,556 The Company expects to perform its performance obligation and recognize the deferred revenue as revenue during the year ended December 31, 2021. 11 Note 5 – Earnings Per Share The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share for three and nine months ended September 30, 2021 and 2020: Schedule of Basic and Diluted Earnings Per Share Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Numerator Net income (loss), as reported $ 11,475,966 $ 15,731,532 $ 29,160,154 $ 29,671,348 Denominator Weighted average shares, basic 28,941,357 28,084,267 28,800,450 26,172,439 Dilutive effect of stock options, warrants and RSUs 1,011,333 1,513,525 1,071,965 1,449,092 Shares used to compute diluted earnings per share 29,952,690 29,597,792 29,872,415 27,621,531 Basic earnings per share $ 0.40 $ 0.56 $ 1.01 $ 1.13 Diluted earnings per share $ 0.38 $ 0.53 $ 0.98 $ 1.07 For the three and nine months ended September 30, 2021, potentially dilutive securities of 50,000 and 147,436 were excluded from the calculation because their effect would have been anti-dilutive. For the three and nine months ended September 30, 2020, potentially dilutive securities of 50,000 were excluded from the calculation because their effect would have been anti-dilutive. Note 6 – Stock-Based Compensation Stock Incentive Plans The Co-Diagnostics, Inc. 2015 Long Term Incentive Plan (the “Incentive Plan”) reserves an aggregate of 6,000,000 shares of common stock issuable upon the grant of awards under the Incentive Plan. The number of awards available for issuance under the Incentive Plan was 2,064,933 at September 30, 2021. Stock Options The following table summarizes option activity during the nine months ended September 30, 2021: Schedule of Option Activity Number of Options Weighted Average Exercise Price Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years) Outstanding at December 31, 2020 1,300,588 $ 2.44 $ 1.24 Granted - - - Expired - - - Forfeited/Cancelled - - - Exercised ( 189,225 ) 2.38 1.12 Outstanding at September 30, 2021 1,111,363 $ 2.12 $ 1.31 7.18 Exercisable at September 30, 2021 1,094,697 $ 2.01 $ 1.18 7.16 The total intrinsic value of options exercised during the nine months ended September 30, 2021 was approximately $ 1.3 million. The aggregate intrinsic value of outstanding options at September 30, 2021 was approximately $ 8.5 million. 12 Stock-based compensation cost is measured at the grant date based on the fair value of the award granted and recognized as expense over the vesting period using the straight-line method. The Company uses the Black-Scholes model to value options granted. In January 2021, the Company modified the exercise price of 100,000 of the options from $ 16.49 to $ 9.30 . Due to the modification, the Company will recognize incremental stock-based compensation cost of $ 65,000 . Of this amount, the Company has recognized approximately $ 50,000 and the remaining will be recognized over the remaining service period. As of September 30, 2021, there were 16,666 of unvested options and $ 119,897 of unrecognized stock-based compensation expense. The unrecognized stock-based compensation expense is expected to be recognized over 0.7 years. Restricted Stock Units The grant date fair value of RSUs granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the awards. The following table sets forth the outstanding RSUs and related activity for the nine months ended September 30, 2021: Schedule of Outstanding Restricted Stock Units and Related Activity Number of RSUs Weighted Average Grant Date Fair Value Unvested at December 31, 2020 522,500 $ 10.49 Granted 1,217,500 9.76 Vested ( 210,834 ) 10.24 Forfeited/Cancelled ( 3,750 ) 10.49 Unvested at September 30, 2021 1,525,416 $ 9.94 As of September 30, 2021, there was approximately $ 13.5 million of unrecognized stock-based compensation expense related to outstanding RSUs which is expected to be recognized over a weighted-average period of 2.5 years. Warrants The Company has issued warrants related to past financings and as compensation to third parties for services provided. The Company estimates the fair value of issued warrants on the date of issuance as determined using a Black-Scholes pricing model. The Company amortizes the fair value of issued warrants using a vesting schedule based on the terms and conditions of each warrant if granted for services. The following table summarizes warrant activity during the nine months ended September 30, 2021: Schedule of Warrant Activity Number of Warrants Weighted Average Exercise Price Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years) Outstanding at December 31, 2020 70,000 $ 1.83 $ 5.21 Granted - - - Forfeited/Cancelled - - - Exercised - - - Outstanding at September 30, 2021 70,000 $ 1.83 $ 5.21 2.5 13 The aggregate intrinsic value of outstanding warrants at September 30, 2021 was approximately $ 553,000 . All outstanding warrants are exercisable at September 30, 2021 and there was no unrecognized stock-based compensation expense related to warrants. Stock Issued for Services The Company has issued restricted stock to third parties for services provided. The grant date fair value of the restricted stock granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the stock awards. The Company has issued 5,548 shares of restricted stock for services during the nine months ended September 30, 2021 and there was no unrecognized stock-based compensation expense related to restricted stock issued. Stock-Based Compensation Expense The Company recognized stock-based compensation expense related to the types of awards discussed above as follows: Schedule of Recognized Stock-based Compensation Expenses Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Options $ 66,247 $ 128,344 $ 219,033 $ 831,542 Restricted stock units 1,344,697 - 3,580,360 - Warrants - - - 303,802 Stock - 914,790 51,900 1,032,032 Total stock-based compensation expense $ 1,410,944 $ 1,043,134 $ 3,851,293 $ 2,167,376 Note 7 – Income Taxes For the three months ended September 30, 2021, the Company recognized an expense from income taxes of $ 2,100,594 , representing an effective tax rate of 15.5 %. For the nine months ended September 30, 2021, the Company recognized an expense from income taxes of $ 6,231,310 , representing an effective tax rate of 17.6 %. The Company’s effective tax rate will generally differ from the U.S. Federal statutory rate of 21.0 % due to state taxes, permanent items, and discrete items. For the three and nine months ended September 30, 2020, the Company recognized a benefit from income taxes of $ 2,914,781 . Note 8 – Related Party Transactions The Company acquired the exclusive rights to the CoPrimer technology pursuant to an exclusive license agreement, dated April 2014 (the “Exclusive License Agreement”), between the Company and DNA Logix, Inc., which was assigned to Dr. Brent Satterfield, a former executive officer, prior to the Company’s acquisition of DNA Logix, Inc. On March 1, 2017, the Company entered into an amendment to its Exclusive License Agreement for its Cooperative Primers (“License”) technology with Dr. Satterfield. The amendment provides in part that all accrued royalties under the License cease as of January 1, 2017, and the Company began in January 2017 to pay to Dr. Satterfield $ 700,000 of accrued royalties at the rate of $ 10,000 per month. At September 30, 2021 and 2020, the aggregate balance of this related party liability was $ 30,000 and $ 120,000 , respectively. Note 9 – Commitments and Contingencies Lease Obligations The Company’s offices are located at 2401 S. Foothill Dr., Suite D, Salt Lake City, Utah 84109-1479. In February 2020, the Company entered into a 4 -year lease agreement for its office space and in March 2020, the Company entered into an addendum with our landlord for additional space. The new aggregate space consists of approximately 13,687 square feet at a monthly rate of $ 28,825 and expires in February 2024 . For the three and nine months ended September 30, 2021, the Company expensed $ 86,588 and $ 259,763 for rent, respectively. For the three and nine months ended September 30, 2020, the Company expensed $ 86,588 and $ 225,374 for rent, respectively. The Company’s future minimum lease payments were as follows as of September 30, 2021: 14 Schedule of Future Minimum Lease Payments Year Ending December 31, 2021 (remainder) $ 71,475 2022 293,595 2023 303,059 2024 50,774 Total lease payments $ 718,903 Litigation Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. In July and September 2020, securities class action complaints were filed by certain stockholders of the Company against the Company claiming that the Company promulgated false and misleading press releases to increase the price of our stock to improperly benefit the officers and directors of the Company. The plaintiffs demand compensatory damages sustained as a result of the Company’s alleged wrongdoing in an amount to be proven at trial. The Company believes these lawsuits are without merit and intends to defend the cases vigorously. The Company is unable to estimate a range of loss, if any, that could result were there to be an adverse final decision in these cases. As of the date of this report, the Company does not believe it is probable that these cases will result in an unfavorable outcome; however, if an unfavorable outcome were to occur in these cases, it is possible that the impact could be material to the Company’s results of operations in the period(s) in which any such outcome becomes probable and estimable. Note 10 – Subsequent Events The Company evaluated subsequent events pursuant to ASC Topic 855 and has determined that there are no events that need to be reported. 15 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations Cautionary Note Regarding Forward-Looking Statements This Quarterly Report on Form 10-Q contains “forward-looking statements” that involve risks and uncertainties. All statements other than statements of historical fact contained in this Quarterly Report and the documents incorporated by reference herein, including statements regarding future events, our future financial performance, business strategy, and plans and objectives of management for future operations, are forward-looking statements. We have attempted to identify forward-looking statements by terminology including “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “should,” or “will” or the negative of these terms or other comparable terminology. Although we do not make forward looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. These statements are only predictions and involve known and unknown risks, uncertainties and other factors and the documents incorporated by reference herein, which may affect our or our industry’s actual results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Moreover, we operate in a highly regulated, very competitive, and rapidly changing environment. New risks emerge from time to time and it is not possible for us to predict all risk factors, nor can we address the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause our actual results to differ materially from those contained in any forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short term and long-term business operations, and financial needs. These forward-looking statements are subject to certain risks and uncertainties that could cause our actual results to differ materially from those reflected in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in this Quarterly Report, and in particular, the risks discussed below and under the heading “Risk Factors” in other documents we file with the SEC. The following discussion should be read in conjunction with the Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on March 25, 2021, and the audited financial statements and notes included therein. You should not place undue reliance on any forward-looking statement, each of which applies only as of the date of this Quarterly Report. Except as required by law, we undertake no obligation to update or revise publicly any of the forward-looking statements after the date of this Quarterly Report to conform our statements to actual results or changed expectations. You are advised, however, to consult any further disclosures we make on related subjects in our periodic and current reports filed with the SEC. You should understand that it is not possible to predict or identify all risk factors. Consequently, you should not consider this list to be a complete set of all potential risks or uncertainties. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation: ● the results of clinical trials and the regulatory approval process; ● our ability to acquire in a timely manner the materials necessary to manufacture our products; ● market acceptance of any products that may be approved for commercialization; ● our ability to protect our intellectual property rights; ● the impact of any infringement actions or other litigation brought against us; ● competition from other providers and products; ● our ability to develop and commercialize new and improved products and services; ● changes in government regulation; and ● and other factors (including the risks contained in the section entitled “Risk Factors” in other documents we file with the SEC) relating to our industry, our operations and results of operations. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results. As used in this Quarterly Report, the terms “we”, “us”, “our”, and “Co-Diagnostics” means Co-Diagnostics, Inc., a Utah corporation and its consolidated subsidiaries (the “Company”), unless otherwise indicated. Executive Overview The following management’s discussion and analysis of financial condition and results of operations describes the principal factors affecting the results of our operations, financial condition, and changes in financial condition. This discussion should be read in conjunction with the accompanying unaudited financial statements and notes thereto included elsewhere in this report. The information contained in this discussion is subject to a number of risks and uncertainties. We urge you to review carefully the section of this report entitled “Cautionary Note Regarding Forward-Looking Statements” for a summary of the risks and uncertainties associated with an investment in our securities. 16 Business Overview Co-Diagnostics, Inc., a Utah corporation (the “Company” or “Co-Dx”), is developing robust and innovative molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. We develop, manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA). In connection with the sale of our tests we may sell diagnostic equipment from other manufacturers as self-contained lab systems (which we refer to as the “MDx Device”). Our diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. Co-Dx’s technical advance involves a novel approach to Polymerase Chain Reaction (“PCR”) test design of primer and probe structure (“CoPrimers”) that eliminates one of the key vexing issues of PCR amplification, the exponential growth of primer-dimer pairs (false positives and false negatives) which adversely interferes with identification of the target DNA/RNA. We believe our proprietary molecular diagnostics technology is paving the way for innovation in disease detection and life sciences research through our enhanced detection of genetic material. Because we own our platform, we believe we will be able to accomplish this faster and more economically, allowing for significant margins while still positioning the Company to be a low-cost provider of molecular diagnostics and screening services. In addition, continued development has demonstrated the unique properties of our CoPrimer technology that make it ideally suited for a variety of applications where specificity is key to optimal results, including multiplexing several targets, enhanced Single Nucleotide Polymorphism (“SNP”) detection and enrichment for next gen sequencing. Our scientists use the complex mathematics of DNA/RNA test design, to engineer and optimize a DNA/RNA test and to automate algorithms that rapidly screen millions of possible options to pinpoint the optimum design. Dr. Satterfield, our founder, developed the Company’s intellectual property consisting of the predictive mathematical algorithms and proprietary reagents used in the testing process, which together represent a major advance in PCR testing systems. Co-Dx technologies are now protected by eight granted or pending US and foreign patents, as well as certain trade secrets and copyrights. Ownership of our proprietary platform permits us the advantage of avoiding payment of patent royalties required by other PCR test systems, which enables the sale of diagnostic tests at a lower price than competitors, while enabling us to maintain profit margins. We design our tests by identifying the optimal locations on the target gene for amplification and pair the location with the optimized primer and probe structure to achieve outputs that meet the design input requirements identified from market research. This is done by following planned and documented processes, procedures and validation protocols. In other words, the data resulting from our tests verify that we succeeded in designing what we intended at the outset. Verification is a series of testing that concludes that the product is ready to proceed to validation in an evaluation either in our lab or in an independent laboratory setting using initial production tests to confirm that the product as designed meets the user needs. In addition to testing for infectious disease, the technology lends itself to identifying any section of a DNA or RNA strand that describe any type of genetic trait, which creates a number of significant applications. We, in conjunction with our customers, are active in designing and licensing tests that identify genetic traits in plant and animal genomes. We also have three multiplexed tests developed to test mosquitos for the identification of diseases carried by the mosquitos to enable municipalities to concentrate their efforts in spraying mosquito populations on the specific areas known to be breeding the mosquitos that carry deadly viruses. Recent Developments Because we believe that testing for the COVID-19 virus is going to be a consideration for public health worldwide even after the current pandemic has subsided, we have initiated a project to facilitate frequent testing in schools, businesses, the hospitality industry, and at home. We believe this may be accomplished through the development of a low cost, easy to use by non-professionals, testing device that can provide PCR quality test results in less than an hour. This project is possible due to the fact that in 2020 we were able to successfully lyophilize our Logix Smart COVID-19 test reagents and additionally developed a saliva-based collection system that does not require the RNA/DNA extraction. While the final result is the same as if done through a lab-based IVD process, it has the advantages of increased speed and ease of handling thanks to lyophilization. We have engaged the services of a group of professionals who have the expertise and track record to develop the hardware for such a device using our CoPrimers as the reagent chemistry. The device will be available to homes, offices, event facilities, and the travel industry at a cost that will allow screening frequently to prevent spread of the COVID-19 virus and its variants in the future. The device would also be available to test for other pathogens detectable through saliva samples as we develop those tests and offer them to the marketplace. 17 RESULTS OF OPERATIONS The Three Months Ended September 30, 2021 Compared to the Three Months ended September 30, 2020 Revenues For the three months ended September 30, 2021, we generated revenues of $30,101,353, compared to revenues of $21,818,753 for the three months ended September 30, 2020. The increase in revenue of $8,282,600 was primarily due to sales of our LogixSmart COVID-19 test developed in response to the current COVID-19 pandemic. Of the total revenue in the three months ended September 30, 2021, $76,945 related to the sale of third party manufactured equipment and consumables, which we sourced and sold to customers to facilitate the sales of our COVID-19 test compared to $1,457,160 of revenue from the sales of such equipment for the three months ended September 30, 2020. Cost of Revenues We recorded cost of revenues of $3,311,255 for the three months ended September 30, 2021, compared to $5,821,281 for the three months ended September 30, 2020. This decrease is due to a reduction of product production costs, reduction in sales of third-party equipment, which have a higher cost of sales than tests, and the commission structure of certain sales of tests completed during the period. Of the total cost of sales during the three months ended September 30, 2021, $50,563 was from equipment sold to our customers compared to $1,213,434 for equipment sold to customers for the three months ended September 30, 2020. Expenses We incurred total operating expenses of $13,159,977 for the three months ended September 30, 2021, compared to total operating expenses of $3,959,270 for the three months ended September 30, 2020. The increase in operating expenses was due to the increase in business activities experienced as a result of our increase in revenue, increased third party sales commissions, reflected in sales and marketing, and increased investment in research and development. General and administrative expenses increased $716,081, from $2,203,417 for the three months ended September 30, 2020 to $2,919,498 for the three months ended September 30, 2021. The increase in general and administrative expenses was primarily due to increased activity to support the growth of our business. The primary drivers of the increased expenses related to increases in compensation including stock-based compensation, insurance expense, contributions to retirement plans and increased expenses for professional services. These increases were partially offset by a reduction of bad debt expense. Our sales and marketing expenses for the three months ended September 30, 2021 were $4,253,091, compared to $798,474 for the three months ended September 30, 2020. The increase of $3,454,617 was primarily a result of increased third-party sales commissions, personnel related expenses, including commissions paid to our sales team, and increased stock-based compensation due to the growth in revenue. Our research and development expenses increased by $4,971,461, from $921,889 for the three months ended September 30, 2020 to $5,893,350 for the three months ended September 30, 2021. The primary increase in expenses was research expenditures of greater than $4,300,000 for our point-of-care device in addition to increases in salaries and related benefits, including stock-based compensation, as we have added additional employees to our research and development team to increase our product development activities. 18 Other Income (Expense) For the three months ended September 30, 2021 we had total other expense of $53,561, compared to total other income of $778,549 for the three months ended September 30, 2020. The decrease was due primarily to a loss from our India joint venture. Net Income We realized net income for the three months ended September 30, 2021 of $11,475,966, compared with net income for the three months ended September 30, 2020 of $15,731,532. The decrease in net income of $4,255,566 was primarily the result of an increase in operating expenses, offset by an increase of product revenues and resulting margins from those sales. Additionally, we recorded income tax expense of $2,100,594 for the three months ended September 30, 2021, compared to an income tax benefit of $2,914,781 for the three months ended September 30, 2020. The Nine Months Ended September 30, 2021 Compared to the Nine Months ended September 30, 2020 Revenues For the nine months ended September 30, 2021, we generated revenues of $77,484,262 compared to revenues of $47,407,555 for the nine months ended September 30, 2020. The increase in revenue of $30,076,707 was primarily due to sales of our LogixSmart COVID-19 test developed in response to the current COVID-19 pandemic. Of the total revenue in the nine months ended September 30, 2021, $507,930 related to the sale of third party manufactured equipment and consumables, which we sourced and sold to customers to facilitate the sales of our COVID-19 test, compared to $3,239,471 of revenue from the sales of such equipment for the nine months ended September 30, 2020. Cost of Revenues We recorded cost of revenues of $9,088,175 for the nine months ended September 30, 2021, compared to $12,278,326 for the nine months ended September 30, 2020. This decrease is due to a reduction of product production costs, reduction in sales of third-party equipment, which have a higher cost of sales than tests, and the commission structure of certain sales of tests completed during the period. Of the total cost of sales during the nine months ended September 30, 2021, $384,602 was from equipment sold to our customers compared to $2,864,829 for equipment sold to customers for the nine months ended September 30, 2020. Expenses We incurred total operating expenses of $32,639,900 for the nine months ended September 30, 2021, compared to total operating expenses of $9,464,699 for the nine months ended September 30, 2020. The increase in operating expenses was due to the increase in business activities experienced as a result of our increase in revenue, increased third party sales commissions, reflected in sales and marketing, and increased investment in research and development. General and administrative expenses increased $2,469,685, from $5,853,935 for the nine months ended September 30, 2020 to $8,323,620 for the nine months ended September 30, 2021. The primary drivers of the increased expenses related to increases in compensation including stock-based compensation, insurance expense, contributions to retirement plans and increased expenses for professional services. These increases were partially offset by a reduction of bad debt expense. Our sales and marketing expenses for the nine months ended September 30, 2021 were $11,303,950, compared to $1,457,148 for the nine months ended September 30, 2020. The increase of $9,846,802 was primarily a result of increased third-party sales commissions, personnel related expenses, including commissions paid to our sales team, and increased stock-based compensation due to the growth in revenue. 19 Our research and development expenses increased by $10,707,413, from $2,072,160 for the nine months ended September 30, 2020 to $12,779,573 for the nine months ended September 30, 2021. The primary increase in expenses was research expenditures of greater than $8,800,000 for our point-of-care device in addition to increases in compensation and related benefits, including stock-based compensation, as we have added additional employees to our research and development team to increase our product development activities. Additionally, there has been an increase in lab supplies expense to further help us in our research and product development activities. Other Income (Expense) For the nine months ended September 30, 2021 we had total other expense of $364,723, compared to total other income of $1,092,037 for the nine months ended September 30, 2020. The decrease in other income was due primarily due to recording a loss of $401,288 from our India joint venture compared to income of $1,016,297 from our joint venture in the same period in 2020. Net Income We realized net income for the nine months ended September 30, 2021 of $29,160,154, compared to net income for the nine months ended September 30, 2020 of $29,671,348. The decrease in net income of $511,194 was primarily the result of sales of our LogixSmart COVID-19 test and resulting margins from those sales offset by increased operating expenses and income taxes. We recorded income tax expense of $6,231,310 for the nine months ended September 30, 2021, compared to an income tax benefit of $2,914,781 for the nine months ended September 30, 2020. Liquidity and Capital Resources At September 30, 2021, we had cash and cash equivalents of $82,658,248 and marketable investment securities of $1,251,285 that could readily be converted into cash if needed. Additionally, our total current assets of September 30, 2021, were $102,287,152 compared to total current liabilities of $4,119,897. Net cash provided by operating activities during the nine months ended September 30, 2021 was $36,202,945, compared to $8,207,340 for the nine months ended September 30, 2020. The increase in cash from operating activities was primarily due to our increased revenue. We received $3,028,192 of cash from investing activities during the nine months ended September 30, 2021 from maturity of marketable investments and repayment of advances from our India joint venture as compared to use of cash of $7,070,183 during the nine months ended September 30, 2020. Net cash provided by financing activities was $450,398 for the nine months ended September 30, 2021 realized from the exercise of options, compared to $19,200,067 for the same period in the prior year. The decrease is primarily due to net proceeds of $18,012,083 received from a series of three registered direct offerings in January and February 2020 pursuant to our shelf registration in addition to receiving $50,000 from the exercise of warrants and options for the nine months ended September 30, 2020. Since commencing sales of our Logix Smart COVID-19 test in March 2020, we have used our cash generated from those sales to fund the increase in our inventories and receivables and pay our operating expenses. We have increased our work force primarily in the area of research and development to complete development of additional tests to enable us to use our distributor network to sell other products throughout the world and remain profitable in the future. We believe that our existing capital resources and the cash generated from future sales will be sufficient to meet our projected operating requirements for the next 12 months. However, our available capital resources may be consumed more rapidly than currently expected and we may need or want to raise additional financing for strategic opportunities. If needed, we expect additional investment capital to come from (i) additional issuances of our common stock with existing and new investors or (ii) the private placement of other securities with investors similar to those that have provided funding in the past. We may not be able to secure such financing in a timely manner or on favorable terms, if at all. 20 On October 30, 2020, we filed a Registration Statement on Form S-3 (File No: 333-249651) with the Securities and Exchange Commission (the “SEC”). The SEC declared the Form S-3 effective on November 5, 2020. Pursuant to a prospectus supplement to the Form S-3, we may offer and sell up to $100 million of the following securities separately or together, in one or more series or classes and in amounts, at prices and on terms described in one or more offerings: common stock; preferred stock; warrants to purchase our securities, each of which may be convertible into equity securities; or units comprised of, or other combinations of, the foregoing securities through underwriting syndicates managed or co-managed by one or more underwriters or dealers, through agents or directly to purchasers. Each time our securities are offered, we will provide a prospectus supplement to the Form S-3 containing more specific information about the particular offering. We have not sold any securities pursuant to the Form S-3. The foregoing estimates, expectations and forward-looking statements are subject to change as we make strategic operating decisions from time to time and as our revenue and expenses fluctuate from period to period. Off-Balance Sheet Arrangements We have no off-balance sheet arrangements. Item 3. Quantitative and Qualitative Disclosures about Market Risk Not required under Regulation S-K for “smaller reporting companies.” Item 4. Controls and Procedures Evaluation of Disclosure Controls and Procedures We maintain “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2021. Based on the evaluation of our disclosure controls and procedures as of September 30, 2021, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls were effective. Changes in Internal Control over Financial Reporting There have been no changes in our internal control over financial reporting during the three months ended September 30, 2021, that have materially affected or, are reasonably likely to materially affect, our internal control over financial reporting. 21 PART II – OTHER INFORMATION Item 1. Legal Proceedings There have been no material developments to the legal proceedings previously disclosed under Item 3 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2020. From time to time, we may become involved in litigation relating to claims arising out of our operations in the normal course of business. Although we have received inquiries from FINRA, NASDAQ and the SEC, to which we have responded, to the best of our knowledge, no governmental authority is contemplating any proceeding to which we are a party or to which any of our properties or businesses are subject, which would reasonably be likely to have a material adverse effect on the Company. Item 1A. Risk Factors. Not required under Regulation S-K for “smaller reporting companies.” Item 2. Unregistered Sales of Equity Securities and Use of Proceeds None. Dividends We have never declared or paid any cash dividends on our capital stock. The payment of dividends on our common stock in the future will depend on our earnings, capital requirements, operating and financial condition and such other factors as our Board of Directors may consider appropriate. We currently expect to use all available funds to finance the future development and expansion of our business and do not anticipate paying dividends on our common stock in the foreseeable future. Pursuant to Section 16-10a-640 of the Utah Revised Business Corporation Act, no distribution may be made if, after giving it effect: (a) the corporation would not be able to pay its debts as they become due in the usual course of business; or (b) the corporation’s total assets would be less than the sum of its total liabilities plus, unless the articles of incorporation permit otherwise, the amount that would be needed, if the corporation were to be dissolved at the time of the distribution, to satisfy the preferential rights upon dissolution of shareholders whose preferential rights are superior to those receiving the distribution. Item 3. Defaults Upon Senior Securities None. Item 4. Mine Safety Disclosures Not applicable. Item 5. Other Information None. 22 Item 6. Exhibits Exhibit Index (a) Exhibits Exhibit Number Description 31.1* Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 31.2* Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 32.1* Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 32.2* Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 101.INS Inline XBRL Instance Document 101.SCH Inline XBRL Taxonomy Extension Schema Document 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document 104 Cover Page Interactive Data File * Filed herewith. 23 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CO-DIAGNOSTICS, INC. Date: November 11, 2021 By: /s/ Dwight H. Egan Name: Dwight H. Egan Title: Chief Executive Officer, President and Principal Executive Officer Date: November 11, 2021 By: /s/ Brian Brown Name: Brian Brown Title: Chief Financial Officer and Principal Financial and Accounting Officer 24